Showing results (1-10 of 55) with videos related to

Sort By:
Pageof 6
Current Pharmaceutical Design|October 8, 2003
Prodrugs in genetic chemoradiotherapyAdam V Patterson, Mark P Saunders, Olga Greco
BMJ (Clinical Research Ed.)|April 6, 2002
Impact on survival of intensive follow up after curative resection for colorectal cancer: systematic review and meta-analysis of randomised trialsAndrew G Renehan, Matthias Egger, Mark P Saunders, et al.
European Journal of Cancer Care|March 27, 2013
Is a nurse-led telephone intervention a viable alternative to nurse-led home care and standard care for patients receiving oral capecitabine? Results from a large prospective audit in patients with colorectal cancerOlive Craven, Carol Anne Hughes, Amy Burton, et al.
Cost Effectiveness and Resource Allocation : C/E|May 13, 2026
Pragmatic health technology appraisals of biosimilars: a pilot case study of bevacizumab in colorectal cancer for NICEMatthew D Stevenson, Mon Mon-Yee, Jessica E Forsyth, et al.
European Radiology|April 20, 2016
The assessment of local response using magnetic resonance imaging at 3- and 6-month post chemoradiotherapy in patients with anal cancerRohit Kochhar, Andrew G Renehan, Damian Mullan, et al.
Annals of Surgical Oncology|November 18, 2022
RAS Mutation Status Should Not Be Used to Predict Outcome from Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Peritoneal MetastasesDilraj Bhullar, Sarah O'Dwyer, Malcolm Wilson, et al.
Cancer Chemotherapy and Pharmacology|February 3, 2009
Vandetanib with FOLFIRI in patients with advanced colorectal adenocarcinoma: results from an open-label, multicentre Phase I studyMark P Saunders, Richard Wilson, Marc Peeters, et al.
Future Oncology (London, England)|May 5, 2018
Management and grading of EGFR inhibitor-induced cutaneous toxicityJanette Beech, Theodora Germetaki, Mary Judge, et al.
Pancreas|December 13, 2005
A phase II study of weekly cisplatin and gemcitabine in patients with advanced pancreatic cancer: is this a strategy still worth pursuing?Alison J Clayton, Abdul W Mansoor, Eileen T Jones, et al.
The Journal of Gene Medicine|April 3, 2007
Hypoxia-targeted over-expression of carboxylesterase as a means of increasing tumour sensitivity to irinotecan (CPT-11)Torkjel Matzow, Rachel L Cowen, Kaye J Williams, et al.
Pageof 6